Skip to main content

Market Overview

BioLineRx Investors: Expect 'Pivotal' Data In Next Few Weeks


In a report published Thursday, Maxim Group analyst Jason Kolbert maintained a Buy rating on BioLine RX Ltd (NASDAQ: BLRX), with a price target of $8, ahead of the BL-1040 pivotal trial data in Europe, expected in the next few weeks.

BL-1040, known as bioabsorbable cardiac matrix or BCM, is "a novel, first-in-class device to prevent left ventricular remodeling and subsequent progression to congestive heart failure in patients who have had a heart attack (acute myocardial infarction)," the report said.

Bellerophon Therapeutics Inc (NASDAQ: BLPH), BiolineRx's partner for BL-1040, announced that all patients had completed follow-ups in June. If statistically significant, the final data may support registration in Europe as early as mid-2016. A US pivotal study is expected next year.

Analyst Jason Kolbert commented, "This is good news for both BiolineRx and Bellerophon. BL-1040 CE mark registration would result in BiolineRx shifting to a commercial stage company from solely development-stage. Combined we see a valuation inflection coming soon if the data is positive."

"We value BioLineRx based on the expected royalties from the products in late-stage development," Kolbert added.

Latest Ratings for BLRX

Feb 2021HC Wainwright & Co.MaintainsBuy
Dec 2020HC Wainwright & Co.MaintainsBuy
Aug 2017OppenheimerInitiates Coverage OnOutperform

View More Analyst Ratings for BLRX
View the Latest Analyst Ratings


Related Articles (BLRX + BLPH)

View Comments and Join the Discussion!

Posted-In: Maxim GroupAnalyst Color Reiteration Analyst Ratings

Latest Ratings

DHIRBC CapitalMaintains104.0
WWEMorgan StanleyMaintains65.0
WSOMorgan StanleyMaintains266.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at